Real World Evidence
Retrospective real-world studies to understand clinical and economic burden of chemotherapy-induced myelosuppression in patients with extensive-stage lung cancer.
This section includes links to Pharmacosmos sponsored-publications and selected Pharmacosmos posters. Information contained in these publications may include information that is inconsistent with the FDA approved use of product(s). Pharmacosmos does not recommend the use of its products in a manner that is inconsistent with FDA-approved labeling. Additionally, the content contained in this section is subject to congress copyright permissions.
*Trilaciclib was developed by G1 Therapeutics which is now subsidiary of Pharmacosmos Therapeutics
October 2023 I Adv Ther
Real-world outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy.
Goldschmidt J, Hart L, Scott J, et al.
October 27-28, 2023 I ASCO (Poster)
Patient characteristics associated with myelosuppression among patients with extensive-stage small cell lung cancer treated with chemotherapy in the community oncology setting.
Goldschmidt J, Monnette A, Shi P, et al.
October 27-28, 2023 I ASCO (Poster)
Burden of myelosuppression in extensive-stage small-cell lung cancer patients receiving chemotherapy: retrospective analysis of real-world data from Tennessee Oncology.
Blakely LJ, Zhou ZY, Edwards ML, et al.
October 27-28, 2023 I ASCO (Poster)
Myelosuppression and healthcare utilization among patients with chemotherapy-treated extensive-stage small cell lung cancer (ES-SCLC) with and without trilaciclib from community oncology practices.
Gajra A, Reeves NP, O’Brien S, et al.
November 2022 I Future Oncology
Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.
Goldschmidt J, Monnette A, Shi P, et al.
April 2022 I J Manag Care Spec Pharm
Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States
Abraham I, Goyal A, Deniz B, et al.
November 2021 I J Med Econ
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy
Abraham I, Onyekwere U, Deniz B, et al.
May 17-20, 2021 | Virtual ISPOR Annual Meeting (Poster)
Cost-benefit analysis of trilaciclib for the prevention of chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer
Deniz B, Onyekwere U, Moran D, et al.
April 12-16, 2021 | Virtual AMCP Annual Meeting (Poster)
A budget impact assessment of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer
Deniz B, Goyal A, Moran D, et al.